An Open-Label, First in Human, Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 in Adult Subjects with Relapsed/Refractory B-Cell and T-Cell Lymphomas

Principal Investigator

Dr Graham Collins

Contact us

Email: orh-tr.earlyphasenurses@nhs.net

IRAS number

1005146